Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson

Mar 27, 2008

NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.

The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Main menu